Figure 5. Effects of PCO371 on bone parameters in OVX rats.

Rats were treated once-daily with PCO371 (p.o.) or hPTH(1–34) (s.c.) for 12 weeks commencing at 12 weeks after OVX surgery. (a,b) BMD of the lumbar spine (L3–L5) (a) and the proximal femur (b). (c) Bone strength in the lumbar spine (L2). (d) Serum osteocalcin levels. (e) Urinary CTX levels. (f) Bone formation in cancellous bone in the lumbar spine (L1), revealed by tetracycline labelling followed by calcein labelling 5 days later. Scale bar, 10 μm. (g) Serum Ca levels on day 84. Data are represented as the mean+s.e.m. of one experiment (n=9 for Sham, n=12 for vehicle and hPTH(1–34), n=10 for 10 mg kg⁻¹ PCO371, n=11 for 3 and 30 mg kg⁻¹ PCO371). Student's t-test was used to compare between the sham and OVX vehicle-treated groups; #P<0.05. Parametric Dunnett's test was used to compare PCO371- or hPTH(1–34)-treated groups with the OVX vehicle-treated group; *P<0.05, **P<0.01, ***P<0.001.